linjc16/ctgov huggingface dataset:
Detoxification and Treatment of Subjects With Medication Overuse Headache

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the benefits of almotriptan used as a transitional therapy and topiramate in subjects with medication overuse headaches (MOH.

Official Title
-----------------
Evaluation of Almotriptan and Topiramate in the Detoxification and Treatment of Subjects With Medication Overuse Headache

Conditions
-----------------
Analgesic Rebound Headache

Intervention / Treatment
-----------------
* Drug: Almotriptan
* Drug: Topiramate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medication overuse headaches 18 years of age and older Must have a diagnosis of probable medication overuse headache Must have greater than fifteen headache days per month Must be in generally good health Female subjects must be postmenopausal or practicing an acceptable method of birth control Exclusion Criteria: Not overusing six or more tablets per day of compounds containing barbituates opioids No overuse of triptans Previous failure or side effects with topiramate or almotriptan Cannot be pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Almotriptan|nan|
|Drug: Topiramate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary measure for the detoxification period |  |  | 
| Number of days with mild or no pain in the first two weeks of treatment |  |  | 
| Primary for the prevention of relapse |  |  | 
| Pain free days through day ninety |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary measure for the detoxification period |  |  | 
| Number of days without any headache in the first two weeks of treatment |  |  | 
| Primary for the prevention of relapse |  |  | 
| Headache frequency through day ninety |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Medication overuse
Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Study Overview
=================
Brief Summary
-----------------
An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

Official Title
-----------------
Sotrovimab Expanded Access Treatment Protocol

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Biological: Sotrovimab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In the opinion of the investigator, meets the current Emergency Use Authorization (EUA) eligibility criteria for sotrovimab OR patients currently hospitalized for a non-COVID-19 illness who acquire COVID-19 (nosocomial infection) and otherwise meets all the current EUA eligibility criteria Exclusion Criteria: Hospitalized due to COVID-19 (excludes nosocomial infection) Require oxygen therapy due to COVID-19, OR who require an increase in baseline oxygen flow rate due to COVID-19

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Sotrovimab|500mg IV|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2, coronavirus, coronavirus disease 2019, COVID-19
Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the immune profile of blast cells and immune effector cells in paired peripheral whole blood and bone marrow samples from AML and MDS patients by standardized flow cytometry. A special emphasis will be focused on monitoring expression of CD200 as well as PGP-170 (MDR1) on blasts cells.

Official Title
-----------------
Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Biological: Blood and Marrow sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 No pregnant woman Patient with myelodysplastic syndrome (with excess blasts) or acute myeloid leukemia Presence of a monitored serum blastose Patient who can obtain free and informed consent (speaks French, no guardianship or curatorship) Exclusion Criteria: Minor Patient (< 18 years old) Medical or psychological Condition that could interact with the ability to understand the study, Pregnant or lactating women, Major persons under guardianship or under the protection of justice Persons deprived of their liberty by a judicial or administrative decision Lack of information and opposition to its participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Blood and Marrow sample|Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial. The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the immune profile of blast cells and immune effector cells in paired peripheral whole blood and bone marrow samples from AML and MDS patients by standardized flow cytometry. |  | 9 mounths |
A Crossover Study in the Treatment of Patients With COPD

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy of Formoterol Fumarate Inhalation Solution (FFIS) 20 mcg BID to Combivent® Inhalation Aerosol [2 inhalations from metered dose inhaler (MDI)of 18 mcg ipratropium bromide and 103 mcg albuterol sulfate QID], and to Compare the preference/compliance of BID nebulization to QID use of MDI

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Drug: Formoterol Fumurate inhalation solution 20 mcg
* Drug: Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of COPD Smoker or exsmoker with at least 10 years smoking at least one pack of cigarettes per day Meet lung function requirements Exclusion Criteria: Diagnosis of Asthma Significant disease other than COPD Female pregnant or lactating or planning to become pregnant

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Formoterol Fumurate inhalation solution 20 mcg|nan|
|Drug: Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung function after 2 weeks of treatment |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung function at each time point, patient questionnaires, medication compliance, |  |  | 
| adverse events, clinical labs, vital signs, ECGs, physical exams |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, Formoterol, Ipratropium, Crossover
Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters

Study Overview
=================
Brief Summary
-----------------
The aim of our prospective study is to construct and validate a non-invasive model consisting biochemical markers, FibroScan, and radiological parameters for evaluating liver fibrosis caused by hepatitis B virus in mainland China.

Detailed Description
-----------------
Up to Oct, 2015,total of 1800 patients with chronic HBV infection were enrolled. Paired blood and liver biopsy samples were collected. Blood samples stored at -80 degree Celsius. Liver biopsy samples were judged by three pathology experts.

Official Title
-----------------
Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus

Conditions
-----------------
Hepatitis B, Liver Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HBsAg positive for at least 6 months agree to have liver biopsy Male or female aged 18 to 65 years old Exclusion Criteria: Patients with alcoholic liver disease, autoimmune liver disease, heretic liver disease, drug induced liver disease,nonalcoholic liver disease or other chronic liver disease platelet count < 80000/L prothrombin activity ≤ 60% patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic infected with hepatitis B virus<br>patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| determine whether a non-invasive test or a combination of non invasive tests may be used to accurately evaluate liver fibrosis in patients with chronic hepatitis B |  | singular evaluation at the time of liver biopsy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biopsy, Fibrosis, Liver Cirrhosis, non-invasive, hepatitis B virus
Uterocervical Angle in the Termination of Second Trimester Pregnancy

Study Overview
=================
Brief Summary
-----------------
To evaluate the performance of uterocervical angle (UCA) in the prediction of second trimester terminations.

Detailed Description
-----------------
Medical termination of pregnancy is a common procedure in obstetrics. In recent years, uterocervical angle (UCA) emerged as a new ultrasound parameter in the prediction of labor. Dziadosz et al concluded that the performance of UCA was even better than the cervical length in their cohort. A wide UCA during second trimester shown to have an increased risk of preterm labor and narrow angle was less likely to have labor. The investigators are aimed to investigate predictive role of both cervical length and UCA in the termination of second trimester pregnancy.The investigators focused on nulliparous women who are taking misoprostol for the cervical preparation and aim to measure their UCA.

Official Title
-----------------
The Predictive Performance of Uterocervical Angle in the Termination of Second Trimester Pregnancy

Conditions
-----------------
Abortion, Second Trimester

Intervention / Treatment
-----------------
* Other: uterocervical angle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nulliparous singleton pregnancy no previous systemic illnesses Exclusion Criteria: abnormal Pap smear previous cesarean section history of dilatation and curettage (D&C) history of LEEP and cervical conization

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Medical induced abortion<br>120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor. | Other: uterocervical angle<br>* uterocervical angle is the angle between lower segment of uterus and cervix<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uterocervical angle | the angle between the lower segment of uterus and cervix | once at the beginning of enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
uterocervical angle, second trimester abortion
Teenage Passenger Influences on Driving Performance of Teenage Drivers

Study Overview
=================
Brief Summary
-----------------
This study, conducted at the University of Massachusetts at Amherst, will examine how male teenage driving performance varies in the presence or absence of male teenage passengers. It will explore what information teen drivers and their passengers use when making decisions that affect their performance on the road. Male drivers under 18 years of age who have a Junior Operator's or Full License and have driven at least once in the month before enrolling in the study may be eligible to participate. In a university laboratory, participants sit in a 1995 Saturn sedan and operate the controls of the car just as they would those of any other car, during simulated drives in urban, suburban and rural areas. They are fitted with a head-mounted eye tracker that records their point of gaze in real time. On one drive, the subject drives alone; on another, a male passenger rides along. After the drives, the subject fills out some questionnaires.

Detailed Description
-----------------
The purpose of this research is to examine how male teenage driving performance varies in the presence or absence of high versus low risk accepting male teenage passengers. Driving performance includes attention and risk measures including eye glance behaviors, speed management, following distance, closing speed and gap acceptance. To what extent does driving performance vary as a product of the male teen passenger risk- acceptance compared with no passenger present?

Official Title
-----------------
Teenage Passenger Influences on the Simulated Driving Performance of Teenage Drivers

Conditions
-----------------
Motor Vehicle Crash Injuries

Intervention / Treatment
-----------------
* Behavioral: Teen Passenger Presence


Participation Criteria
=================
Eligibility Criteria
-----------------
INCLUSION CRITERIA: Only male driver and passengers Under the age of 18 Having a provisional or full license (i.e. allowing driving without supervision) Having driven in the past 3 months Having normal or corrected-to-normal vision (i.e. contact lenses or eye glasses are accepted) EXCLUSION CRITERIA: Females Motion sickness

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Teen Passenger Presence|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risky Driving Behavior |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Simulated Driving, Risky Driving Behavior, Social Influences
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

Study Overview
=================
Brief Summary
-----------------
Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The investigators and others have shown that less toxic preparative regimens (reduced intensity or 'mini' transplants) allow reliable allogeneic engraftment and durable remissions, significantly broadening the population of patients who may be offered this therapy to those who are older and more infirmed. The field is now focusing on the period post transplant for approaches to immune recovery leading to improved outcomes. The primary objective of this registry is to catalogue data from patients who undergo standard of care reduced intensity allogeneic transplantation.

Detailed Description
-----------------
Subjects will have toxicity monitored and reported per the Center for International Blood and Marrow Transplant Research (CIBMTR) program standard and as required by law for bone marrow transplant (BMT) reporting in the USA. Data will be collected from physical exam, laboratory studies, radiographs that are performed for clinical purposes. The tests and procedures are not in addition or in excess of our standards for allogeneic transplant outside of this registry. Data about donors will also be collected.

Official Title
-----------------
Registry Study of T Cell Depleted Allogeneic Non-Myeloablative Stem Cell Transplant Recipients

Conditions
-----------------
Myeloma, Hodgkin's Disease, Non Hodgkin's Lymphoma, Leukemia, Myelodysplasia

Participation Criteria
=================
Eligibility Criteria
-----------------
Recipient Inclusion Criteria: Subjects ≥ 18 years of age undergoing a reduced intensity allogeneic transplant Exclusion Criteria: Subjects < 18 years of age Subjects not undergoing nonmyeloablative or ablative allogeneic transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Reduced Intensity Allogeneic Transplant<br>Subjects undergoing a reduced intensity allogeneic stem cell transplant | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Catalogue Data | Catalogue data from subjects who undergo standard of care reduced intensity allogeneic transplantation. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stem cell transplantation, non-myeloablative
Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome

Study Overview
=================
Brief Summary
-----------------
Evaluate about age of resolution in immune defect in 22q11.2 Deletion Syndrome Incidence of immunodeficiencies in 22q11.2 Deletion Syndrome

Detailed Description
-----------------
22q11.2 Deletion Syndrome is the most common for microdeletion syndrome. The incidence is about 1:4000 of live birth. Clinical features in this syndrome are vary which consist of conotruncal cardiac anomalies, developmental disabilities, palatal anomalies, speech delay, hypocalcemia, characteristic facial features and immunodeficiencies. The most common type of immunodeficiencies is T cell defect that associated with thymic hypoplasia. In the present time, the investigators don't know about the resolution of immune defect in this syndrome.

Official Title
-----------------
Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome

Conditions
-----------------
Immune Defect, 22q11.2 Deletion Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 22q11.2 deletion syndrome patients in allergy and immunology clinic, genetic clinic, cardio clinic, genetic clinic and development clinic Exclusion Criteria: loss follow up in 22q11.2 deletion syndrome patients or incomplete medical record

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| age of resolution in immune defect in 22q11.2 Deletion Syndrome |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of immunodeficiencies in 22q11.2 Deletion Syndrome |  | 18 months | 
| type of infectious disease in 22q11.2 Deletion Syndrome |  | 18 months |